Startseite
English
Erweiterte Suche
Durchblättern nach ...
Publikationen im Überblick
Ansprechpartner
Hilfe
DOI
PMC
 |
|
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Exploiting common aspects of obesity and cancer cachexia for future therapeutic strategies.
Curr. Opin. Pharmacol. 53, 101-116 (2020)
Obesity and cancer cachexia are diseases at opposite ends of the BMI. However, despite the apparent dichotomy, these pathologies share some common underlying mechanisms that lead to profound metabolic perturbations. Insulin resistance, adipose tissue lipolysis, skeletal muscle atrophy and systemic inflammation are key players in both diseases. Several strategies for pharmacological treatments have been employed in obesity and cancer cachexia but demonstrated only limited effects. Therefore, there is still a need to develop novel, more effective strategies. In this review we summarize existing therapies and discuss potential novel strategies that could arise by bridging common aspects between obesity and cachexia. We discuss the potential role of macrophage manipulation and the modulation of inflammation by targeting Nuclear Receptors (NRs) as potential novel therapeutic strategies.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten
[➜Einloggen]
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Review
Schlagwörter
Necrosis-factor-alpha; Adipose-tissue Inflammation; Type-2 Diabetes-mellitus; Cell Lung-cancer; Double-blind; Skeletal-muscle; Tnf-alpha; Insulin Sensitivity; Ppar-gamma; Antibody Treatment
ISSN (print) / ISBN
1471-4892
e-ISSN
1471-4973
Zeitschrift
Current opinion in pharmacology
Quellenangaben
Band: 53,
Seiten: 101-116
Verlag
Elsevier
Verlagsort
London
Nichtpatentliteratur
Publikationen
Begutachtungsstatus
Peer reviewed
Institut(e)
Institute of Diabetes and Cancer (IDC)
Förderungen
Deutsche Forschungsgemeinschaft DFG
Helmholtz Future Topic Aging and Metabolic Reprogramming (AMPro)
Helmholtz Future Topic Aging and Metabolic Reprogramming (AMPro)